Advertisement Covers CROI 2017


Harnessing Vaginal Microbiota to Protect Women From HIV: What We Know and Don't Know

March 16, 2017

 1  |  2  |  Next > 

If you're a provider, you want to offer patients the latest, evidence-based ways to reduce their risk for HIV -- including women who may have increased risk not because of their behavior or even the prevalence of unsuppressed HIV in their community, but because of the microbes in their genital tracts.

But, if you ask R. Scott McClelland, M.D., M.P.H., associate director of the University of Washington Center for AIDS Research, the role of the microbiome in women's HIV risk is still not totally clear.

"Moving forward, investigating the effect of the [vaginal] microbiome together with the effects on the immune system is critically important," he said. "I think that to some extent the microbiota shapes the mucosal immune response, and the mucosal immune response may shape the microbiota. Fully disaggregating those relationships may be difficult, but I do think that's a critical way forward."

Related: The Company You Keep: Do Social Networks Influence HIV Status?

At the Conference on Retroviruses and Opportunistic Infections (CROI 2017) last month, however, we got closer to understanding some of those relationships -- as well as the limits of current research.


A Milieu Whose Time Has Come?

The vaginal microbiome became a central topic of discussion at 2016's International AIDS Conference, when Salim Abdool Karim, M.D., Ph.D., director of the Center for AIDS Research Program in South Africa (CAPRISA), released an analysis showing that the bacteria Prevotella bivia was associated with a 13-fold increase in HIV prevalence. At the same conference, McClelland presented a poster showing that other bacteria -- Eggerthella species type 1, Gemella asaccharolytica, Leptotrichia/Sneathia, Megasphaera and Mycoplasma hominis -- were associated with statistically significant increases in HIV prevalence, but no where near a 13-fold increased risk.

Then, in January, researchers at the Harvard Medical School lab of Douglas Kwon, M.D., Ph.D., found that diverse microbiomes -- that is, microbiomes not dominated by Lactobacillus crispatus -- were associated with a four-fold increase in HIV prevalence. What's more, the report, published in the journal Immunity, found that such microbiomes were also associated with increased activation of mucosal CD4 cells. In other words, those bacteria were associated with the availability of more HIV target cells on the surface of a woman's genital tract.

When Kwon's team looked more closely, they saw that some of the same bacteria described by Karim and McClelland -- Prevotella, Megasphaera and Sneathia, for instance -- were associated with increased vaginal inflammation and HIV prevalence.

The findings, the team wrote in the paper, could have bearing for wide swaths of women in sub-Saharan Africa.

"Our findings further indicate that individuals within a particular [bacterial community] group are at similar risk of acquiring HIV," they wrote. "This suggests that more than half the population of young black South African women is at increased HIV infection risk based on the composition of their cervicovaginal microbiome."

Kwon's lab's study was one of several McClelland included in his survey on the vaginal microbiome and HIV risk. Here's what we do know, based on numerous presentations and posters released at CROI last month.

Vaginal Microbiota May Thin the Defenses Against HIV

It's long been known that domination of the vaginal microbiota by Lactobacillus crispatus (L. crispatus) is associated with lower pH and lower HIV acquisition. But in a poster presented at CROI on Wednesday, Feb. 15, Julie K. Shade and colleagues at Johns Hopkins University presented data showing that it's not just the low pH that inhibit HIV acquisition; something else, something that's not totally clear yet, is at work.

The study asked women aged 18-45 to collect a sample of their vaginal mucus. Then, the researchers challenged the samples with HIV to see how mobile the virus is in L. crispatus microbiomes versus more diverse microbiomes, sometimes referred to as vaginal dysbiosis or simply bacterial vaginosis (BV).

They found that HIV slipped through the mucus of women with BV easily but was "trapped" in the lower-pH mucus of women with Lactobacillus-dominant microbiota. The more the virus is trapped in the mucus, the less likely it is to reach whatever target cells are present on the surface of the genital tract.

Then, to test whether the trap was set by the pH or the bacteria itself, Shade and colleagues altered the pH of both the samples containing high amounts of Lactobacillus and those samples without. Again, they challenged the samples with HIV.

They found that even the Lactobacillus-laden mucus thinned at a higher pH. But when the pH again dropped? The trap was again set.

"In contrast," the researchers wrote, "acidification of cervicovaginal mucus from women with BV did not lead to the trapping of HIV."

In other words, it's not just the pH; something specific about L. crispatus inhibits HIV from reaching the genital surface.

BV Is Hard to Dislodge

In his presentation, McClelland described the other challenge of diagnosing a woman with BV. Namely, even with the approved treatments for BV, there's only an 80% initial cure rate.

"And then, in women initially cured, [there is] about a 50% failure rate by six months recurrence and even higher over longer periods," he said. "So, simply treating BV once isn't going to be the answer."

He added that there's not much in the pipeline in terms of new BV regimens, though some groups are working on probiotics and other approaches to manage the microbiome to become a more advantageous ecosystem.

Circumcision's Role in Altering the Microbiome

The vaginal microbiota doesn't exist in isolation, after all. McClelland has told in the past that BV may simply be a marker of condomless sex with uncircumcised men. So, the penile microbiota is important to a woman's HIV risk, as well.

At CROI, Lance Price, Ph.D., a professor of science and engineering at George Washington University, presented data led by researcher Cindy M. Lui testing the hypothesis that male circumcision alters the penile microbiota, thereby decreasing the production of cytokines and target cells and resulting in lower HIV risk for men overall.

What Liu's team found was that Prevotella shows up again -- this time in the penile microbiota of men living with HIV at baseline, but not in their HIV-negative counterparts.

A year after circumcision, the swabs returned a totally different result.

"The microbial communities changed dramatically a year after circumcision," Price said. Specifically, he said, they saw significant decreases in anaerobic bacteria -- that is, the bacteria associated with BV in women.

"You'll recognize some of these names: Prevotella, Porphyromonas, Finegoldia, etc.," he said.

Not only that, circumcised men showed evidence of new bacteria taking their place, including Lactobacillus.

This also points to a challenge in dislodging high-risk microbes from women's microbiota, Price told They had to literally remove skin to dislodge high-risk microbes from men's penises. There's no such option available to women who wish to change their microbiome.

 1  |  2  |  Next > 

Related Stories

Mapping the Microbiome: Vaginal Bacteria and HIV Risk
More HIV Research Highlights From CROI 2017

This article was provided by TheBodyPRO. It is a part of the publication The 24th Conference on Retroviruses and Opportunistic Infections.

No comments have been made.

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read's Comment Policy.)

Your Name:

Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:

Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.


The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.